The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.
Charles River Laboratories International, Inc. (CRL)
Common Stock · Currency in USD · XNYS
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Company Info
SIC8731
Composite FIGIBBG000BG5BL8
CIK0001100682
IPOJun 23, 2000
Sectorservices-commercial physical & biological research
Highlights
Market Cap$8.58B
EPS$4.44
P/E Ratio38.61
Revenue$4.07B
Gross Profit$4.02B
Net Income$222.22M
Employees19,700
WSO49,341,960
Phone781-222-6000
Websitehttps://www.criver.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Charles River Laboratories International, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Charles River Laboratories International, Inc. (CRL) has returned -13.11% so far this year and 30.95% over the past 12 months. Looking at the last ten years, CRL has achieved an annualized return of 8.41%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
CRL
1M-2.13%
6M-2.39%
YTD-13.11%
1Y30.95%
5Y-10.61%
10Y8.41%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Charles River Laboratories International, Inc. (CRL) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.17% | -14.54% | -1.59% | 0.07% | ||||||||
| 2025 | -11.86% | 2.17% | -9.27% | -21.34% | 13.61% | 12.56% | 12.34% | -1.96% | -2.79% | 15.39% | -0.18% | 12.50% |
| 2024 | -7.79% | 17.57% | 6.59% | -15.54% | -9.30% | -1.46% | 17.66% | -19.15% | 0.89% | -8.36% | 10.34% | -7.70% |
| 2023 | 10.41% | -9.81% | -7.70% | -5.47% | 1.63% | 8.38% | -0.12% | -0.57% | -6.39% | -13.85% | 17.46% | 20.38% |
| 2022 | -12.44% | -12.30% | -1.68% | -15.59% | -2.37% | -9.03% | 16.60% | -17.01% | -3.36% | 7.26% | 5.34% | -5.87% |
| 2021 | 2.88% | 9.17% | -0.06% | 13.85% | 0.26% | 9.19% | 10.09% | 8.60% | -6.84% | 8.74% | -18.27% | 3.03% |
| 2020 | 0.20% | -0.07% | -19.50% | 19.55% | 26.96% | -2.60% | 11.98% | 8.50% | 3.21% | -0.14% | 1.72% | 5.58% |
| 2019 | 10.91% | 14.94% | 1.57% | -4.31% | -11.24% | 12.84% | -6.35% | -3.32% | 1.68% | -2.42% | 10.69% | 4.34% |
| 2018 | -3.98% | 0.97% | 0.14% | -2.01% | 3.57% | 3.79% | 11.56% | -0.40% | 8.96% | -9.96% | 10.51% | -17.60% |
| 2017 | 5.35% | 7.66% | 2.64% | -0.12% | 2.29% | 9.32% | -3.36% | 10.08% | -0.84% | 7.63% | -10.63% | 5.04% |
| 2016 | 5.13% | 7.90% | -3.90% | 6.47% | -5.34% | 0.05% | -8.51% | -6.37% | 6.77% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of CRL compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Charles River Laboratories International, Inc. volatility is 3.57%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 7.14B | 7.53B | 8.20B | 7.60B | 7.02B | 5.49B | 4.69B | 3.86B | 2.93B | 2.71B | 2.07B | 1.89B | 1.64B | 1.59B | 1.56B |
| Temporary Equity (USD) | 41.26M | 41.13M | 56.72M | 42.43M | 53.01M | 25.50M | 28.65M | 18.53M | 16.61M | 14.66M | 28.01M | 28.42M | 20.58M | - | - |
| Equity Attributable To Parent (USD) | 3.16B | 3.46B | 3.60B | 2.98B | 2.53B | 2.11B | 1.63B | 1.32B | 1.05B | 836.77M | 733.07M | 672.20M | 640.98M | 600.81M | 525.58M |
| Equity Attributable To Noncontrolling Interest (USD) | 5.30M | 5.45M | 5.39M | 4.79M | 4.16M | 3.57M | 3.24M | 2.45M | 2.33M | 2.36M | 4.49M | 3.72M | 3.09M | 2.40M | 1.78M |
| Equity (USD) | 3.17B | 3.47B | 3.60B | 2.98B | 2.54B | 2.12B | 1.64B | 1.32B | 1.05B | 839.13M | 737.56M | 675.93M | 664.66M | 603.20M | 527.36M |
| Redeemable Noncontrolling Interest (USD) | 41.26M | 41.13M | 56.72M | 42.43M | 53.01M | 25.50M | 28.65M | 18.53M | 16.61M | 14.66M | 28.01M | 28.42M | 20.58M | - | - |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | 348.81M | 316.18M | 247.92M | 176.94M | 130.93M | 69.88M | - | 96.26M |
| Long-term Debt (USD) | - | - | - | - | - | - | - | 1.61B | 1.09B | 1.18B | 814.24M | 753.75M | 663.05M | 666.45M | 717.90M |
| Noncurrent Liabilities (USD) | 2.80B | 3.03B | 3.48B | 3.49B | 3.40B | 2.51B | 2.32B | 1.96B | 1.40B | 1.43B | 991.17M | 884.68M | 732.93M | 640.90M | 814.16M |
| Other Current Liabilities (USD) | 702.66M | 674.35M | 672.86M | 688.59M | 588.94M | 510.45M | 440.07M | 354.76M | 284.62M | 267.64M | 202.25M | 190.79M | 156.80M | 264.08M | 140.86M |
| Wages (USD) | 268.85M | 179.42M | 213.29M | 197.08M | 246.12M | 206.82M | 158.62M | 137.21M | 101.04M | 93.47M | 72.83M | 71.57M | 58.46M | 46.95M | 41.60M |
| Accounts Payable (USD) | 148.80M | 140.34M | 168.94M | 205.92M | 198.13M | 122.48M | 111.50M | 66.25M | 77.84M | 68.49M | 36.68M | 33.82M | 31.77M | 31.22M | 34.33M |
| Current Liabilities (USD) | 1.12B | 994.10M | 1.06B | 1.09B | 1.03B | 839.75M | 710.18M | 558.22M | 463.50M | 429.59M | 311.76M | 296.17M | 247.03M | 342.25M | 216.80M |
| Liabilities (USD) | 3.92B | 4.02B | 4.54B | 4.58B | 4.43B | 3.35B | 3.03B | 2.52B | 1.87B | 1.86B | 1.30B | 1.18B | 979.96M | 983.14M | 1.03B |
| Other Non-current Assets (USD) | 4.03B | 4.52B | 4.95B | 4.70B | 4.46B | 3.17B | 2.63B | 2.03B | 1.32B | 1.30B | 550.50M | 422.62M | 331.35M | 299.15M | 301.01M |
| Intangible Assets (USD) | - | - | - | - | - | - | - | - | - | - | 280.80M | 178.88M | 84.54M | 84.92M | 93.44M |
| Fixed Assets (USD) | 1.66B | 1.60B | 1.64B | 1.47B | 1.29B | 1.12B | 1.04B | 932.88M | 781.97M | 755.83M | 677.96M | 676.80M | 676.18M | 717.02M | 738.03M |
| Noncurrent Assets (USD) | 5.69B | 6.13B | 6.59B | 6.16B | 5.75B | 4.29B | 3.67B | 2.96B | 2.10B | 2.05B | 1.51B | 1.28B | 1.09B | 1.10B | 1.13B |
| Other Current Assets (USD) | 1.05B | 1.02B | 1.14B | 1.09B | 981.41M | 918.72M | 808.08M | 716.50M | 675.13M | 526.68M | 435.30M | 490.96M | 443.10M | 376.38M | 310.05M |
| Prepaid Expenses (USD) | 96.11M | 103.21M | 87.88M | 89.34M | 93.54M | 96.71M | 52.59M | 53.45M | 36.54M | 34.32M | 30.20M | 26.90M | 20.06M | 20.40M | 22.83M |
| Inventory (USD) | 299.10M | 278.54M | 380.26M | 255.81M | 199.15M | 185.70M | 160.66M | 127.89M | 114.96M | 95.83M | 93.74M | 89.04M | 89.40M | 88.47M | 92.97M |
| Current Assets (USD) | 1.45B | 1.40B | 1.61B | 1.44B | 1.27B | 1.20B | 1.02B | 897.84M | 826.63M | 656.83M | 559.23M | 606.90M | 552.55M | 485.25M | 425.84M |
| Assets (USD) | 7.14B | 7.53B | 8.20B | 7.60B | 7.02B | 5.49B | 4.69B | 3.86B | 2.93B | 2.71B | 2.07B | 1.89B | 1.64B | 1.59B | 1.56B |
News and Insights
Charles River Laboratories announced significant divestiture plans, selling its CDMO and Cell Solutions businesses to GI Partners, and certain European Discovery Services assets to IQVIA Holdings. The divestitures will reduce 2026 revenue by over $200 million but are expected to improve adjusted operating margins by at least 100 basis points and add approximately 10 cents to adjusted EPS. The company raised its fiscal 2026 adjusted earnings guidance to $10.80-$11.30.
The global Adeno Associated Virus (AAV) vector manufacturing market is projected to grow from USD 2.84 billion in 2025 to USD 9.87 billion by 2035, at a CAGR of 13.4%. Growth is driven by increased clinical trials, regulatory approvals of AAV-based gene therapies, technological innovations in manufacturing processes, and rising demand from pharmaceutical companies and CDMOs. North America leads the market while Asia Pacific shows the fastest growth rate.
The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.
The global innovative drug CRO market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, with a 5.44% CAGR, driven by increasing R&D costs, clinical trial complexities, and technological advancements.
Charles River Laboratories reported Q3 2025 earnings beating expectations, with revenue of $1.01 billion, but lowered full-year guidance and announced strategic asset sales, causing stock to decline.
The global cell-based assays market is projected to grow from USD 17.11 billion in 2023 to USD 35.34 billion by 2032, driven by increasing demand in drug discovery, toxicity testing, and advanced biotechnology research.
The global cell and gene therapy quality control market is projected to grow from $2.87 billion in 2025 to $22.81 billion by 2034, with a 25.74% CAGR. North America currently leads the market, while Asia Pacific is expected to witness the fastest growth, driven by technological advancements and increasing demand for personalized therapies.
The global biologics safety testing market is projected to grow from $4.58 billion in 2025 to $14.45 billion by 2034, with a 13.64% CAGR. North America dominates the market, driven by biopharmaceutical R&D and technological advancements, while Asia-Pacific shows rapid growth potential.
The global pharmaceutical contract research organization (CRO) services market is projected to grow at a 10% CAGR, reaching USD 25 billion by 2035, driven by increasing outsourcing trends in drug discovery and development across North America and Europe.